FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to					
Section 16. Form 4 or Form 5					
obligations may continue. See					
Instruction 1(b).					

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     McCarthy Sean A.						2. Issuer Name and Ticker or Trading Symbol  CytomX Therapeutics, Inc. [ CTMX ]								Relationship eck all appli X Directo	*		son(s) to Is		
(Last) (First) (Middle) C/O CYTOMX THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 05/19/2023								X Officer below)		CEO	Other below)	(specify	
151 OYSTER POINT BLVD., STE. 400						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SOUTH SAN FRANCISCO CA 94080														X Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City)	(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - N	on-Deri	<i>r</i> ative	Sec	curit	ies Ac	quired	, Di	sposed o	of, or Be	neficial	ly Owne	d				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day)					Exe if a	ny	ned n Date, Day/Year)	3. Transac Code (II 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 5)				s ally following	Form:	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common	mmon Stock 05/19/20				2023				М		16,535	A	\$1.574	9 405,	356(1)		D		
Common Stock													93,158				See footnote <sup>(2)</sup>		
		Т	able II								oosed of converti			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$1.5749	05/19/2023			М			16,535	(3)		02/08/2025	Common Stock	16,535	\$0	119,5	36	D		

## **Explanation of Responses:**

- 1. Includes 161,250 restricted stock units.
- 2. Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.
- 3. This option is fully vested and exercisable.

/s/ Lloyd Rowland, as 05/23/2023 Attorney-in-Fact for Sean A. **McCarthy** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.